Big pharma, big money, big risks - does a charity have a role in biotech and pharma innovation?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Big pharma, big money, big risks - does a charity have a role in biotech and pharma innovation?
-
ナレーター：
-
著者：
このコンテンツについて
A recent report from Deloitte has shed new light on the staggering cost of developing new drugs - an expense that now exceeds $2 billion per therapy on average. It's a cost only matched by the huge risk in undertaking the research and development needed to get a drug or intervention to market. So, is the 'innovation economy' of drug discovery sustainable? What can - perhaps should - be done about this? And does a charity like CRUK have a role here? Time to get some perspective on all this from Iain Foulkes...
Some useful links:
Cancer Research Horizons is CRUK's innovation engine built to complement it's network of researchers. They take innovations from the lab bench to the bedside, translating them into effective treatments and diagnostics for cancer patients - https://www.cancerresearchhorizons.com/
The report from Deloitte showing the staggering cost of developing new drugs—an expense that now exceeds $2 billion per therapy on average.
FDA Commissioner Rob Califf says drug prices are too high.
Hosted on Acast. See acast.com/privacy for more information.